NSW annual report describing adverse events following immunisation, 2011.

Deepika Mahajan, Su Reid, Jane Cook, Kristine Macartney, Robert I Menzies
{"title":"NSW annual report describing adverse events following immunisation, 2011.","authors":"Deepika Mahajan,&nbsp;Su Reid,&nbsp;Jane Cook,&nbsp;Kristine Macartney,&nbsp;Robert I Menzies","doi":"10.1071/NB12081","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This report summarises Australian passive surveillance data for adverse events following immunisation in NSW for 2011.</p><p><strong>Methods: </strong>Analysis of de-identified information on all adverse events following immunisation reported to the Therapeutic Goods Administration.</p><p><strong>Results: </strong>449 adverse events following immunisation were reported for vaccines administered in 2011; this is slightly higher than in 2010 (n=439) and the second highest number since 2003. The most commonly reported reactions were injection site reaction, fever, allergic reaction and malaise. A large number of injection site reactions were reported following administration of the 23-valent pneumococcal polysaccharide vaccine in adults aged 65 years and over (97.4/100000 doses) and in children aged less than 7 years following administration of the 13-valent pneumococcal conjugate vaccine (29.4/100000 doses) and combined diphtheria, tetanus, pertussis (acellular) and inactivated poliovirus (quadrivalent)-containing vaccines (47.1/100000 doses). Only 10% of the reported adverse events were categorised as serious. There were two reports of death however both were attributed to causes other than vaccination.</p><p><strong>Conclusion: </strong>The increased number of reports in 2011 is attributable to the high rates of injection site reactions in children associated with the administration of combined diphtheria, tetanus, pertussis (acellular) and inactivated poliovirus (quadrivalent)-containing vaccines and the 13-valent pneumococcal conjugate vaccine, as well as in adults following receipt of the 23-valent pneumococcal polysaccharide vaccine.</p>","PeriodicalId":29974,"journal":{"name":"NSW Public Health Bulletin","volume":"23 9-10","pages":"187-200"},"PeriodicalIF":0.0000,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1071/NB12081","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NSW Public Health Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1071/NB12081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Aim: This report summarises Australian passive surveillance data for adverse events following immunisation in NSW for 2011.

Methods: Analysis of de-identified information on all adverse events following immunisation reported to the Therapeutic Goods Administration.

Results: 449 adverse events following immunisation were reported for vaccines administered in 2011; this is slightly higher than in 2010 (n=439) and the second highest number since 2003. The most commonly reported reactions were injection site reaction, fever, allergic reaction and malaise. A large number of injection site reactions were reported following administration of the 23-valent pneumococcal polysaccharide vaccine in adults aged 65 years and over (97.4/100000 doses) and in children aged less than 7 years following administration of the 13-valent pneumococcal conjugate vaccine (29.4/100000 doses) and combined diphtheria, tetanus, pertussis (acellular) and inactivated poliovirus (quadrivalent)-containing vaccines (47.1/100000 doses). Only 10% of the reported adverse events were categorised as serious. There were two reports of death however both were attributed to causes other than vaccination.

Conclusion: The increased number of reports in 2011 is attributable to the high rates of injection site reactions in children associated with the administration of combined diphtheria, tetanus, pertussis (acellular) and inactivated poliovirus (quadrivalent)-containing vaccines and the 13-valent pneumococcal conjugate vaccine, as well as in adults following receipt of the 23-valent pneumococcal polysaccharide vaccine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
描述免疫接种后不良事件的新南威尔士州年度报告,2011年。
目的:本报告总结了澳大利亚新南威尔士州2011年免疫接种后不良事件的被动监测数据。方法:分析向药品管理局报告的免疫接种后所有不良事件的去识别信息。结果:2011年报告了449例接种疫苗后免疫不良事件;这一数字略高于2010年(n=439),是2003年以来第二高的数字。最常见的反应是注射部位反应、发热、过敏反应和不适。在65岁及以上的成年人(97.4/100000剂)和7岁以下的儿童(47.1/100000剂)接种了13价肺炎球菌结合疫苗(29.4/100000剂)和白喉、破伤风、百日咳(无细胞)和灭活脊髓灰质炎病毒(四价)联合疫苗(47.1/100000剂)后,报告了大量注射部位反应。报告的不良事件中只有10%被归类为严重。有两份死亡报告,但都归因于接种疫苗以外的原因。结论:2011年报告数量的增加是由于儿童注射部位反应的高发率与接种白喉、破伤风、百日咳(无细胞)和灭活脊髓灰质炎病毒(四价)联合疫苗和13价肺炎球菌结合疫苗有关,以及在接受23价肺炎球菌多糖疫苗后的成人注射部位反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
20 weeks
期刊最新文献
Transition of the NSW Public Health Bulletin to Public Health Research & Practice. Reflections on 24 years of the NSW Public Health Bulletin. Reporting postpartum haemorrhage with transfusion: a comparison of NSW birth and hospital data. Timeliness of Salmonella Typhimurium notifications after the introduction of routine MLVA typing in NSW. Public and private dental services in NSW: a geographic information system analysis of access to care for 7 million Australians.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1